Malignant Neoplastic Disease clinical trials at UC Health
1 research study open to eligible people
MRTX849 in Patients With Cancer Having a KRAS G12C Mutation
open to eligible people ages 18 years and up
Evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
at UC Irvine
Last updated: